Rethinking obesity treatment with new GLP-1 receptor drugs

Incretin-based therapies are increasingly utilized for obesity management, prompting discussions about their potential to rival metabolic bariatric surgery (MBS).

• Both incretin-based therapies and metabolic bariatric surgery (MBS) are considered for obesity treatment.
• Effectiveness, limitations, and costs of both treatment options are compared.
• Obesity care pathways may evolve as new treatments are integrated into practice.
• Key evidence gaps remain that need to be addressed for a clearer understanding of the roles of incretin-based therapies and MBS.

Simplified